Merus (NASDAQ:MRUS) had its price target lowered by analysts at Citigroup from $18.00 to $16.00 in a research report issued on Friday. The firm presently has a “neutral” rating on the biotechnology company’s stock. Citigroup‘s price target suggests a potential upside of 27.90% from the stock’s current price.
Other analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Merus from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Friday. BidaskClub upgraded shares of Merus from a “sell” rating to a “hold” rating in a research report on Thursday, March 7th. Finally, ValuEngine upgraded shares of Merus from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $21.67.
Shares of NASDAQ MRUS traded down $0.62 during trading on Friday, hitting $12.51. The company had a trading volume of 2,788 shares, compared to its average volume of 25,588. Merus has a fifty-two week low of $11.00 and a fifty-two week high of $26.74. The firm has a market cap of $303.29 million, a price-to-earnings ratio of -2.92 and a beta of -0.12.
Merus (NASDAQ:MRUS) last announced its earnings results on Thursday, December 27th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter. Merus had a negative net margin of 140.49% and a negative return on equity of 55.96%. The company had revenue of $7.57 million during the quarter, compared to analyst estimates of $4.25 million. Equities analysts expect that Merus will post -2.18 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in MRUS. JPMorgan Chase & Co. boosted its position in Merus by 33.8% during the third quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock worth $350,000 after acquiring an additional 4,476 shares during the last quarter. Artal Group S.A. acquired a new position in Merus during the fourth quarter worth about $2,886,000. Aquilo Capital Management LLC boosted its position in Merus by 3.6% during the third quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock worth $25,577,000 after acquiring an additional 44,799 shares during the last quarter. Laurion Capital Management LP acquired a new position in Merus during the third quarter worth about $2,104,000. Finally, Acadian Asset Management LLC acquired a new position in Merus during the third quarter worth about $537,000. Institutional investors and hedge funds own 58.76% of the company’s stock.
Merus Company Profile
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
Recommended Story: Discount Rate
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.